Hypomethylating agent - PDFSEARCH.IO - Document Search Engine

Hypomethylating agent
Results: 32

#	Item
11	First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Jean Pierre Issa, MD Fels Institute, Temple Univ Add to Reading List Source URL: astx.com Language: English Triazines Acute leukemia Myeloid leukemia Acute myeloid leukemia Orphan drugs Azacitidine DNA methyltransferase Leukemia Epigenetics Oncology Medicine Nucleosides
12	First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous hypomethylating agent, in 102 patients with Intermediate or High Risk MDS or CMML On Behalf of the SGI-110 Investigative Team Guillerm Add to Reading List Source URL: astx.com Language: English Pharmacology Azacitidine lactams Chemistry Decitabine Hypomethylating agent DNA methyltransferase Nucleosides Triazines Medicine
13	Abstract No[removed]Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML) Simone Jueliger1, Add to Reading List Source URL: astx.com Language: English Epigenomics Methylation DNA methylation Hypomethylating agent Acute myeloid leukemia Cellular differentiation Genetics Biology Epigenetics
14	SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Fo Add to Reading List Source URL: astx.com Language: English - Date: 2012-12-13 18:06:00 Hypomethylating agent Health Toxicology Medicine Myelodysplastic syndrome Syndromes
15	Abst. No[removed]Preclinical Data in Cynomolgus Monkeys of ASTX727, a novel oral hypomethylating agent (HMA) composed of low-dose oral decitabine combined with a novel Cytidine Deaminase Inhibitor (CDAi) E7727 Aram Oganesi Add to Reading List Source URL: astx.com Language: English - Date: 2013-12-09 05:38:21 Hypomethylating agent Myelodysplastic syndrome
16	Abst. No. 678 Evaluation of Oral Bioavailability and Intermittent Dosing Schedules for Pharmacodynamic Effects by SGI-110, a Novel Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA), in Male Cynomolgus Monke Add to Reading List Source URL: astx.com Language: English - Date: 2013-07-16 08:37:55 Piperazines Norfloxacin
17	Microsoft PowerPoint - LLS1104 - MDS slides - on background v14 (for pdf) [Compatibility Mode] Add to Reading List Source URL: www.cancereducation.com Language: English - Date: 2015-04-02 11:28:05 Nucleosides Triazines Immunosuppressants Lenalidomide Azacitidine Decitabine Erythropoietin International Prognostic Scoring System Hypomethylating agent Medicine Oncology Pharmacology
18	RESULTS OF A RANDOMIZED MULTICENTER PHASE 2 STUDY OF A 5-DAY REGIMEN OF SGI-110, A NOVEL HYPOMETHYLATING AGENT, IN TREATMENT NAÏVE ELDERLY ACUTE MYELOID LEUKEMIA NOT ELIGIBLE FOR INTENSIVE THERAPY Karen Yee, MD Add to Reading List Source URL: astx.com Language: English Myeloid leukemia Magnesium in biology Medicine Matter Biology Acute leukemia Acute myeloid leukemia
19	11th International Congress on Targeted Anticancer Therapies Paris, March 4-6, 2013 IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING Add to Reading List Source URL: astx.com Language: English Triazines Epigenetics Hypomethylating agent DNA methyltransferase Decitabine Azacitidine DNA methylation Methylation Cell culture Biology Chemistry Nucleosides
20	Microsoft PowerPoint - 2014_SGI-110_Poster_AACR_abst_2321_Oganesian_final-print Add to Reading List Source URL: astx.com Language: English - Date: 2014-06-09 09:38:33 Stem cells Bone marrow Circulatory system Lymphatic system Skeletal system Hypomethylating agent Polonium Bone Anatomy Matter Biology

UPDATE